GlaxoSmithKline (NYSE:GSK) and Sunwin Stevia International (OTCMKTS:SUWN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.
Valuation and Earnings
This table compares GlaxoSmithKline and Sunwin Stevia International’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|GlaxoSmithKline||$43.10 billion||2.19||$5.93 billion||$3.17||11.89|
|Sunwin Stevia International||$26.09 million||N/A||-$1.38 million||N/A||N/A|
This table compares GlaxoSmithKline and Sunwin Stevia International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sunwin Stevia International||-6.34%||-22.38%||-5.72%|
Institutional & Insider Ownership
11.0% of GlaxoSmithKline shares are owned by institutional investors. 10.0% of GlaxoSmithKline shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of recent recommendations for GlaxoSmithKline and Sunwin Stevia International, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sunwin Stevia International||0||0||0||0||N/A|
Risk and Volatility
GlaxoSmithKline has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Sunwin Stevia International has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
GlaxoSmithKline beats Sunwin Stevia International on 8 of the 9 factors compared between the two stocks.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Sunwin Stevia International Company Profile
Sunwin Stevia International, Inc. produces and sells natural sweeteners and other pharmaceutical products primarily in the People's Republic of China. It operates through two segments, Stevioside; and Corporate and Other Pharmaceutical. The company produces and sells various steviol glycosides with rebaudioside A and stevioside as the principal components. It provides Steviosin, a low calorie stevia extract for medicinal use; and OnlySweet, a zero calorie tabletop sweetener to food and drug manufacturers, and ingredient distributor foreign trade companies. The company also produces and sells Metformin, a medication for the treatment of type 2 diabetes. Sunwin Stevia International, Inc. is based in Qufu, China.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.